JT
SRPT icon

Jump Trading’s Sarepta Therapeutics SRPT Stock Holding History

Jump Trading’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,800
Closed -$786K – 194
2016
Q3 		$786K Buy
+12,800
New +$387K 0.09% 77
2015
Q3 		– Sell
-2,300
Closed -$70K – 860
2015
Q2 		$70K Buy
+2,300
New +$47K ﹤0.01% 917

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jump Trading's SRPT Position: Q4 2016 in Review

Jump Trading sold out of Sarepta Therapeutics (SRPT) in Q4 2016, closing a stake of 1,833 shares — an estimated $113K sold.

Jump Trading first reported a position in SRPT in Q3 2014 and held it in 3 quarters. The position peaked at $113K in Q3 2016. 178 funds tracked by Wall St. Rank hold SRPT as of Q4 2016.

  • Jump Trading reported no remaining Sarepta Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Jump Trading sold 1,833 Sarepta Therapeutics shares in Q4 2016, an estimated $113K.
  • Jump Trading first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 3 quarters.
  • Jump Trading's Sarepta Therapeutics position peaked at $113K in Q3 2016.
  • 178 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2016.

Based on Jump Trading's 13F filing for Q4 2016, filed 13 Feb 2017.